While Rigel is still determining final results for the fourth quarter of 2025, the company expects to report fourth quarter total revenue of $69.8 million, compared to$57.6 million for the same period of 2024. Rigel expects to report fourth quarter of 2025 gross product sales of $84.5 million. Net product sales are expected to be$65.4 million, compared to $46.5 million for the same period of 2024, including: ® TAVALISSE (fostamatinib disodium hexahydrate) net product sales of$45.6 million compared to $31 ...